Source: Antimicrobial Agents and Chemoterapy. Unidade: FM
Assunto: HEPATITE B
ABNT
NITA, S. Kioko Ono et al. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemoterapy, v. 46, n. 8, p. 2602-2605, 2002Tradução . . Acesso em: 31 out. 2024.APA
Nita, S. K. O., Kato, N., Shiratori, Y., Carrilho, F. J., & Omata, M. (2002). Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemoterapy, 46( 8), 2602-2605.NLM
Nita SKO, Kato N, Shiratori Y, Carrilho FJ, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemoterapy. 2002 ; 46( 8): 2602-2605.[citado 2024 out. 31 ]Vancouver
Nita SKO, Kato N, Shiratori Y, Carrilho FJ, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemoterapy. 2002 ; 46( 8): 2602-2605.[citado 2024 out. 31 ]